Acrolein activates matrix metalloproteinases by increasing reactive oxygen species in macrophages
Introduction
Atherosclerotic disease leading to myocardial infarction (MI) and stroke is the leading cause of morbidity and mortality in the Western world (Rosamond et al., 2008). It is currently believed that atherosclerotic lesions develop and grow as a result of vascular inflammation that leads to monocyte infiltration into the vessel wall. Once lodged in the sub-intimal space, the monocytes differentiate into macrophages which take up modified lipoproteins and as a result are transformed into foam cells (Glass and Witztum, 2001, Reiss and Glass, 2006). These processes lead to the formation of distinct lesions (plaque) which are composed of foam cells, a lipid-rich-core and a fibrous, matrix-rich cap. Gradual erosion of this cap or its acute rupture exposes platelets to the underlying matrix proteins and pro-thrombotic molecules, activating them and initiating a thrombotic response. Vascular occlusion at these sites initiates ischemic episodes associated with myocardial and cerebral infarction.
Although physiological events contributing to plaque erosion and rupture are complex, matrix metalloproteinases (MMPs) have been suggested to be play an important role (Galis et al., 1994, Galis et al., 1995, Herman et al., 2001, Sukhova et al., 1999). MMP-mediated degradation of the extracellular matrix (ECM) is vital for several physiological functions including development, morphogenesis, angiogenesis, and tissue repair. Several pathological conditions, such as arthritis, cancer, nephritis, chronic ulcers, and fibrosis (Nagase et al., 2006) are, however, associated with excessive or unregulated MMP activity. MMP dysregulation is also a characteristic feature of cardiovascular abnormalities and increased levels of MMPs have indeed been found in atherosclerotic plaques (Galis et al., 1994, Galis et al., 1995, Halpert et al., 1996, Rajavashisth et al., 1999) and in patients with unstable angina or acute myocardial infarction (Kai et al., 1998, Tziakas et al., 2004).
Acrolein is an aldehydic compound that has been linked in epidemiological studies to cardiovascular pathology (Bhatnagar, 2004, Feron et al., 1991). It is a particularly abundant component of air-borne particulate matter (PM) that arises during the burning of fossil fuels, cigarettes, or other organic material. In addition, acrolein is generated during the cooking or frying of food, is present in the effluent of industrial waste, and exists naturally in vegetables, fruits, and herbs (Feron et al., 1991). Acrolein is also an end product of the metabolism of certain pharmaceuticals (Ludeman, 1999) and can likewise be produced by myeloperoxidase-catalyzed oxidation. It is therefore generated in high amounts at sites of inflammation (Anderson et al., 1997) or lipoprotein oxidation (Anderson et al., 1997, Burke et al., 2001, Feron et al., 1991, Steinberg, 1997), particularly within vascular lesions (Shao et al., 2005). The toxicity of acrolein is a consequence of its strongly reactive, electrophilic, carbonyl group which can react with cellular nucleophiles such as thiols or amines (Esterbauer et al., 1991). Thus acrolein can form adducts with proteins, disrupting cellular signaling or function, or nucleic acids, eliciting mutagenic or carcinogenic effects. In addition, the toxic effects of acrolein can result from indirect means. In particular, chronic acrolein exposure could deplete cellular antioxidants such as glutathione, rendering the cell prone to damage from free radicals. Cardiovascular tissue seems to be particularly sensitive to the toxic effects of acrolein. Epidemiological and animal studies have linked acrolein exposure to arrhythmia (Bhatnagar 1995), hypertension (Feron et al., 1991), atherogenesis (Steinbrecher et al., 1990), dyslipidemia (McCall et al., 1995), and myocardial infarction (Alfredsson et al., 1993, Levine et al., 1984, Stewart et al., 1990). Despite these associations however, the precise mechanisms whereby acrolein contributes to acute cardiovascular pathology is unknown.
Given the extensive evidence implicating oxidative stress in MMP activation (Nelson and Melendez, 2004), we tested the hypothesis that acrolein exposure results in MMP activation and thus contributes to acute plaque rupture and vascular occlusion. Using both a cell culture model and murine atherosclerotic tissue, we did indeed demonstrate that one consequence of acrolein exposure is MMP secretion. Furthermore we show that this was dependent upon increased intracellular calcium and increased ROS generation by xanthine oxidase. Our findings are likely to be of significance in understanding the acute inflammatory responses to acrolein generated endogenously or delivered from the environment.
Section snippets
Reagents and cells
The fluorescent reagents H2DCFDA, fluo-4 AM and DQ-gelatin were purchased from Invitrogen (Carlsbad, CA) while BAPTA-AM and apocynin were from Calbiochem (Gibbstown, NJ). Cell culture media (RPMI 1640) was obtained from Mediatech Inc. (Manassas, VA) and additional media components, fetal calf serum, glutamine, and penicillin/streptomycin were from Clonetics (Allendale, NJ). The MMP-9 antibody, low melting temperature agarose and all other chemicals and reagents were obtained from Sigma (St.
Exposure to acrolein stimulates MMP-9 and ROS in differentiated THP-1 cells
To begin to examine the effect of acrolein on MMPs, we used a macrophage cell line. Macrophages are a major cell component of atherosclerotic lesions (Gerrity, 1981a, Gerrity, 1981b). They express high levels of MMPs that are activated in response to oxidative, pathogenic, and inflammatory stimuli. Hence, we examined whether acrolein also affects MMP production by macrophages. For this, we utilized PMA-differentiated THP-1 cells, a widely used macrophage model. After differentiation in to
Discussion
The major findings of this study are that exposure to acrolein increases intracellular calcium which in turn activates XO in human macrophages. These increases were furthermore associated with an increase in ROS generation and MMP-9 secretion (Fig. 7). Conversely, we found that inhibition of XO prevented ROS generation and decreased MMP-9 secretion from acrolein-treated macrophages. Finally, our experiments with advanced arterial lesions of apoE-null mice showed that treatment with acrolein
Conflict of interest statement
The authors report no conflicts of interest.
Acknowledgments
This work was supported in part by a grant from EPA, NIH grants ES11860, HL55477, HL59378, and a grant from Philip Morris.
References (78)
- et al.
Gelatinase-mediated migration and invasion of cancer cells
Biochim. Biophy. Acta
(2005) - et al.
Catecholamine monoamine oxidase a metabolite in adrenergic neurons is cytotoxic in vivo
Brain Res.
(2001) - et al.
4-Hydroxynonenal triggers Ca2+ influx in isolated rat hepatocytes
Biochem. Biophys. Res. Commun.
(1996) - et al.
Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes
Free Radic. Biol. Med.
(1991) - et al.
Aldehydes: occurrence, carcinogenic potential, mechanism of action and risk assessment
Mutat. Res.
(1991) - et al.
Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase
J. Biol. Chem.
(2001) - et al.
Reduction of reperfusion injury of human myocardium by allopurinol: a clinical study
Free Radic. Biol. Med.
(1995) - et al.
Atherosclerosis. the road ahead
Cell
(2001) - et al.
Conversion of xanthine dehydrogenase to xanthine oxidase during ischemia of the rat small intestine and the effect of trifluoperazine on the conversion
J. Pediatr. Surg.
(1993) - et al.
Activation of protein kinase Czeta is essential for cytokine-induced metalloproteinase-1, -3, and -9 secretion from rabbit smooth muscle cells and inhibits proliferation
J. Biol. Chem.
(2002)